The coronavirus disease 2019 (COVID-19) has impacted healthcare systems and economies worldwide. Diabetes mellitus (DM) is another disease with global implications. Continuous glucose monitoring (CGM) systems have become a valuable tool for monitoring glucose levels and trends around the clock. This study sought to demonstrate that COVID-19 and diabetic patients with CGM are linked to better outcomes than those without CGM. The University of California, Davis Health System’s (UCDHS) electronic health record (EHR) data and the analytical platform ATLAS were used. The following outcomes were defined: visits to the emergency room (ER), hospital stays, mechanical ventilation (MV), deaths, and glycated hemoglobin (A1c). ATLAS found 8,576 (11.51%) patients confirmed to have a positive COVID-19 result. Of them, 1,514 (17.65%) had a diagnosis of diabetes. 24 (1.59%) of them had a CGM, and 1,490 (98.41%) did not have a CGM. The ATLAS results support that COVID-19 and diabetic patients with CGM had better outcomes than those without CGM.